New research from MSK decodes how mesothelioma evades #immunotherapy; shows why a common kidney cancer treatment combination falls short; and supports a free, open-source #AI-driven drug discovery initiative. Learn more: https://bit.ly/4uZZDHb

New study alert: Roni Shouval & team evaluated the frequency of second primary malignant neoplasms among those with #Lymphoma or #Myeloma who received T-cell–engaging bispecific antibodies. @mskcancercenter.bsky.social#Lymphoma#Myeloma Read the study: https://bit.ly/4vYu0yL

Now in Cancer Discovery @aacrjournals.bsky.social: Deconvolving SARS-CoV-2 mRNA Vaccine Impact on Immunotherapy-related Survival - by Justin Jee, @sawyerslabmskcc.bsky.social, Nikolaus Schultz, et al. doi.org/10.1158/2159... @mskcancercenter.bsky.social

MSK researchers are helping advance #MorPhiC, an international effort to determine the biological functions of the roughly 20,000 protein-coding genes in the human genome.

MSK scientists have uncovered a hidden role for RNA. Researchers led by MSK molecular and cell biologist @christinemayr.bsky.social found that RNA can act as a critical regulatory proteins, revealing a previously unknown function of RNA. Learn more: https://bit.ly/3QpBprx

mRNA 3′ UTRs chaperone intrinsically disordered regions to control protein activity @cellcellpress.bsky.social @mskcancercenter.bsky.social @christinemayr.bsky.social www.cell.com/cell/fulltex...

🎉 Congrats to MSK's most recent awards & appointments, including Dr. Yelena Janjigian, Dr. Samuel Cytryn, and Dr. Jeremy Tchack for being awarded funding by the Torrey Coast Foundation; Dr. Scott Lowe for receiving the 2026 Lotus Award; and more: www.mskcc.org/news-release...

📢 New Review Published in EXO! Title: Ferroptosis spreading through propagative signals By Drs. Saloni K. Hombalkar, Jyotirekha Das, and Michael Overholtzer from @mskcancercenter.bsky.social 🔗 Open access: sciexplor.com/exo/articles... #Ferroptosis #CellDeath #RedoxBiology

Missed some of the research presented by MSK experts at #ASCO26? We've rounded up selected highlights spanning sarcoma, liver cancer, lung cancer, prostate cancer, blood cancers, and more: https://bit.ly/3Qfyv8Q

Closing out strong, join MSK radiation oncologist Dr. Amy Xu at #ASCO26 as she presents results from a phase II study evaluating genomically personalized radiation dose de-escalation in patients with pathogenic ATM mutations. 🕒 Tuesday, June 2 | 10:39 a.m. CDT Learn more: https://bit.ly/4x1m1ST

Coming up at #ASCO26: Join #melanoma medical oncologist Dr. Alexander Shoushtari for a presentation on how new tumor-infiltrating lymphocyte research can be translated into real benefit for patients. @mskcancercenter.bsky.social#ASCO26#melanoma 🕒 Monday, June 1 | 5:30 p.m. CDT Learn more: https://bit.ly/4nX5jjg

Join MSK's Dr. Michael Morris at #ASCO26 as he presents results from CONVERGE-01 Part 3 evaluating Ac-225 rosopatamab tetraxetan in patients w/ metastatic castration-resistant #prostatecancer previously treated with Lu-PSMA therapy. Learn more: meetings.asco.org/meetings/202...

Join MSK thoracic medical oncologist Dr. Jamie Chaft at #ASCO26 as she presents results from the phase III ALCHEMIST trial evaluating nivolumab after surgery and adjuvant chemotherapy in patients with non-small cell lung cancer. 🕒 Monday, June 1 | 1:15 p.m. CDT Learn more: https://bit.ly/3Q9i1Pw

Join MSK medical oncologist Dr. Darren Feldman at #ASCO26 for an education session on optimizing treatment for patients with poor-risk testicular cancer, including a discussion on the management of brain metastasis. 🕒 Monday, June 1 | 1:51 p.m. CDT Learn more: https://bit.ly/4uEc3VN

🚨 New findings presented at #ASCO26: An international phase 3 clinical trial led by MSK's Dr. Ghassan K. Abou-Alfa found that adding dual immunotherapy to TACE significantly increased progression-free survival for people with hepatocellular carcinoma (HCC).

Presenting our new study at #ASCO26 right now! Provider profits on cancer drugs have grown 4-fold to $40 billion in the last decade and a half. @ascocancer.bsky.social @mskcancercenter.bsky.social @hannahrabrams.bsky.social @nihcm.bsky.social

Join MSK sarcoma medical oncologist Dr. Mark Dickson at #ASCO26 as he participates as an expert in a case-based panel discussion on consensus and controversies in well-differentiated/dedifferentiated retroperitoneal liposarcoma. 🕒 Monday, June 1 | 11:30 a.m. CDT Learn more: https://bit.ly/4ojpetb

Presenting at #ASCO26 now! Our new study: Bribes from the drug industry can lead oncologists to use WORSE treatments (not just better ones) @ascocancer.bsky.social @mskcancercenter.bsky.social @dusetzinas.bsky.social @commonwealthfund.org @nihcm.bsky.social @arnoldventures.bsky.social

Join MSK hematology/oncology fellow Dr. Eric Jurgens at #ASCO26 for a poster on CAR T-cell detection and clonality in immune effector cell-associated enterocolitis after ciltacabtagene autoleucel. @mskcancercenter.bsky.social#ASCO26 🕒 Monday, June 1 | 9 a.m. CDT Learn more: https://bit.ly/4dEWXcK

Starting soon at #ASCO26: Dr. Ying Liu will present a poster on the NRG-GY036 trial comparing one vs. two years of maintenance olaparib (±bevacizumab) in #BRCA-mutated or HRD+ #OvarianCancer. @mskcancercenter.bsky.social#ASCO26#BRCA🕒 Monday, June 1 | 9 a.m. CDT Learn more: https://bit.ly/49zWDcJ

Join MSK thoracic medical oncologist Dr. Kathryn Arbour at #ASCO26 as she presents an overview of the latest advances in targeting #KRAS G12-mutant cancers. Not to be missed! @mskcancercenter.bsky.social @kcarbourmd.bsky.social#ASCO26#KRAS 🕒 Monday, June 1 | 10:36 a.m. CDT Learn more: https://bit.ly/3RHEfZl

Join MSK radiation oncologist Dr. Luke Pike at #ASCO26 as he presents research on a machine learning-driven model designed to help predict brain metastasis risk in patients with breast cancer. 🕒 Monday, June 1 | 9:57 a.m. CDT Learn more: https://bit.ly/4fnVLfb

Join MSK gastrointestinal medical oncologist Dr. Ghassan Abou-Alfa at #ASCO26 as he presents efficacy and safety results from the phase 3 EMERALD-3 study. 🕒 Monday, June 1 | 9:45 a.m. CDT Learn more: https://bit.ly/4ecVY3A

Join MSK genitourinary medical oncologist Dr. Darren Feldman at #ASCO26 as he presents final results from a phase 2 trial of cabozantinib plus nivolumab for non-clear cell #RenalCellCarcinoma. @mskcancercenter.bsky.social#ASCO26#RenalCellCarcinoma 🕒 Monday, June 1 | 9:12 a.m. CDT Learn more: https://bit.ly/4fiMdC6

WATCH: Alan L. Ho, MD, PhD, discusses the rationale for evaluating a ROR2-targeting antibody-drug conjugate in oropharyngeal squamous cell carcinoma. @mskcancercenter.bsky.social #hncsm #oncology See our head and neck cancers page for more insights! www.onclive.com/clinical/hea...

Join MSK head and neck medical oncologist Dr. Alan Ho at #ASCO26 to learn about a phase 2 study of darolutamide plus leuprolide acetate for recurrent or metastatic AR-positive salivary gland cancer. @mskcancercenter.bsky.social#ASCO26 🕒 Monday, June 1 | 8:48 a.m. CDT Learn more: https://bit.ly/3QdafEg

Join MSK medical oncology fellow Dr. Ziad El Bakouny at #ASCO26 for a poster on the clinical and genomic factors that drive immune-related side effects across cancer types. @mskcancercenter.bsky.social#ASCO26 🕒 Monday, June 1 | 9 a.m. CDT Learn more: https://bit.ly/4wY4ue6

⚠️ New findings presented in the plenary session at #ASCO26 suggest daraxonrasib could help usher in a new era of treatment for metastatic pancreatic cancer.

🔬 A phase 3 clinical trial led by MSK experts found that #abemaciclib, a targeted therapy already approved for certain breast cancers, can significantly slow the growth of dedifferentiated liposarcoma, a rare and aggressive soft tissue cancer w/ few effective treatment options after it has spread.

Research co-authored by MSK gastrointestinal medical oncologist Dr. Eileen O’Reilly will be presented during the plenary session at #ASCO26.

Research co-authored by MSK's Dr. Alexander Drilon will be presented during the plenary session at #ASCO26. The phase 3 LIBRETTO-432 trial evaluated adjuvant selpercatinib in patients with stage IB-IIIA RET fusion-positive non-small cell lung cancer. #NSCLC 🕒 Sunday, May 31 | 2:13 p.m. CDT

Join MSK sarcoma medical oncologist Dr. Mark Dickson at #ASCO26 as he presents results from the phase 3 SARCO41 study evaluating abemaciclib in patients with advanced dedifferentiated #liposarcoma. 🕒 Sunday, May 31 | 1:39 p.m. CDT Learn more: https://bit.ly/49uhzSt

Join @breastcancerdoc.bsky.social at #ASCO26 for post-progression treatment analyses from the phase 3 evERA trial of giredestrant plus everolimus in ER-positive, HER2-negative advanced #BreastCancer. @mskcancercenter.bsky.social#ASCO26#BreastCancer 🕒 Sunday, May 31 | 12 p.m. CDT Learn more: https://bit.ly/4dOEsBh

Join MSK's Dr. Saad Usmani at #ASCO26 as he presents results from the phase 3 CEPHEUS study evaluating daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in transplant-ineligible patients with newly diagnosed #mm. 🕒 Sunday, 5/31 | 10:21 a.m. CDT Learn more: https://bit.ly/49ujp5P

Join MSK radiation oncologist Dr. Nancy Lee at #ASCO26 for a clinical science symposium on FMISO PET-guided radiation dose de-escalation in HPV-associated oropharyngeal cancer. 🕒 Sunday, May 31 | 10:09 a.m. CDT Learn more: https://bit.ly/4u5Obta

Join MSK genitourinary medical oncologist Dr. Jonathan Rosenberg at #ASCO26 as he moderates a case-based panel on biomarker-driven treatment strategies for #BladderCancer, with the patient at the center. @mskcancercenter.bsky.social#ASCO26#BladderCancer 🕒 Sunday, May 31 | 8 a.m. CDT Learn more: https://bit.ly/49pCK8k

Join MSK thoracic medical oncologist Dr. Cardinale Smith at #ASCO26 as she chairs a "Highlights of the Year" session, spotlighting the most important advances across oncology. @mskcancercenter.bsky.social#ASCO26 🕒 Sunday, May 31 | 8 a.m. CDT Learn more: https://bit.ly/4uHQrIg

Join MSK melanoma medical oncologist Dr. James Smithy at #ASCO26 as he presents results from a phase 2 trial evaluating IO102-IO103 in combination w/ nivolumab-relatlimab in patients with previously untreated, unresectable #melanoma. 🕒 Sat, May 30 | 5:36 p.m. CDT Learn more: https://bit.ly/4u73WQz

Join MSK's Dr. Monica Chen at #ASCO26 as she presents results from a phase 1b study evaluating the MEK inhibitor PF-07799544 in combination with the BRAF inhibitor PF-07799933 in patients with advanced BRAF-mutant melanoma. 🕒 Saturday, May 30 | 4:30 p.m. CDT Learn more: https://bit.ly/4u73WQz

Join MSK lymphoma specialist Dr. Alison Moskowitz at #ASCO26 to learn about innovative therapies for T-cell #Lymphoma and relapsed #HodgkinLymphoma. @mskcancercenter.bsky.social#ASCO26#Lymphoma#HodgkinLymphoma🕒 Saturday, May 30 | 4:36 p.m. CDT Learn more: https://bit.ly/4vdbthB

Join gastrointestinal medical oncologist Dr. Eileen O'Reilly at #ASCO26 for an education session on novel approaches and future directions in targeting KRAS-driven cancers, beyond the G12C mutation. @mskcancercenter.bsky.social#ASCO26 🕒 Saturday, May 30 | 1:49 p.m. CDT Learn more: https://bit.ly/43BGCPZ

Join MSK hematologist Dr. Jodi Mones at #ASCO26 for a poster on global phase 3 trial results of hetrombopag for patients with chemotherapy-induced #Thrombocytopenia. @mskcancercenter.bsky.social#ASCO26#Thrombocytopenia 🕒 Saturday, May 30 | 1:30 p.m. CDT Learn more: https://bit.ly/4fR96wt

Join MSK breast medical oncologist Dr. Ezra Rosen at #ASCO26 as he presents a poster on the first-in-human phase 1/2 ERADIC8 study evaluating EXT-19477, an investigational PARG inhibitor, in patients w/ advanced solid tumors. 🕒 Sat, May 30 | 1:30 – 4:30 p.m. CDT Learn more: https://bit.ly/4x3mwvO

Strong start to day two of #ASCO26: MSK’s Dr. Sherry Shen shared topics including weight management, lifestyle interventions, and emerging research on #GLP1 medications.

Join Dr. Yelena Janjigian at #ASCO26 for her poster on first-line trastuzumab deruxtecan (T-DXd)-based regimens in advanced HER2-expressing gastric, gastroesophageal junction, & esophageal cancers from the DESTINY-Gastric03 study. 🕒 Sat, 5/30 | 9 a.m.–12 p.m. CDT Learn more: https://bit.ly/4fN7K5V

Today at #ASCO26: Join MSK's Dr. Neil Segal for his poster on a phase 2 study evaluating adjuvant botensilimab and balstilimab in patients with microsatellite-stable #colorectalcancer and persistent circulating tumor DNA following surgery and chemotherapy. Learn more: https://bit.ly/3PA8lNT

Join MSK breast medical oncologist Dr. Sherry Shen at #ASCO26 as she discusses managing obesity after a breast cancer diagnosis, from behavior change to the potential role of GLP-1 therapies. @mskcancercenter.bsky.social#ASCO26 🕒 Saturday, May 30 | 8:24 a.m. CDT Learn more: https://bit.ly/4u2NXmo

Join MSK breast medical oncologist Dr. Mark Robson at #ASCO26 for the symposium “Multicancer Early Detection: Potential Versus Proof.” 🕒 Saturday, May 30 | 8:24 a.m. CDT Learn more: https://bit.ly/4u05EmJ

Join MSK interventional radiologist Dr. Stephen B. Solomon at #ASCO26 as he shares an interventional #radiology perspective during a care-based panel discussion. 🕒 Saturday, May 30 | 8:00–9:00 a.m. CDT Learn more: https://bit.ly/4eelaGQ

About to begin at #ASCO26: MSK thoracic medical oncologist Dr. Robert Daly will present a pragmatic trial using telehealth to support extended dosing of the #immunotherapy pembrolizumab and reduce in-person visits. @ascocancer.bsky.social